FT576 in Subjects With Multiple Myeloma

Study Number

1059520

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.

Check your eligibility for this trial

Check now

Full Title

(FT576-101) A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

ClinicalTrials.Gov ID

NCT05182073

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.